APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biologics Monoclonal Antibodies Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Biologics Monoclonal Antibodies Drug Market Analysis and Forecast 2026-2032

Report ID 173970760221 December 2025192 pages

Choose your research edition.

Industry ResearchBiologics Monoclonal Antibodies Drug Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics Monoclonal Antibodies Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Biologics Monoclonal Antibodies Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics Monoclonal Antibodies Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics Monoclonal Antibodies Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Biologics Monoclonal Antibodies Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Biologics Monoclonal Antibodies Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biologics Monoclonal Antibodies Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Biologics Monoclonal Antibodies Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biologics Monoclonal Antibodies Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Biologics Monoclonal Antibodies Drug include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Biogen and Amgen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biologics Monoclonal Antibodies Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biologics Monoclonal Antibodies Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Biologics Monoclonal Antibodies Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biologics Monoclonal Antibodies Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biologics Monoclonal Antibodies Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Biologics Monoclonal Antibodies Drug revenue, projected growth trends, production technology, application and end-user industry.

Biologics Monoclonal Antibodies Drug Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Biogen

Amgen

AbbVie

Sobi

Innovent Biologics

Biologics Monoclonal Antibodies Drug Segment by Type

Trastuzumab

Rituximab

Infliximab

Adalimumab

Other

Biologics Monoclonal Antibodies Drug Segment by Application

Cancer

Autoimmune Disease

Other

Biologics Monoclonal Antibodies Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics Monoclonal Antibodies Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics Monoclonal Antibodies Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics Monoclonal Antibodies Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Biologics Monoclonal Antibodies Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Biologics Monoclonal Antibodies Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologics Monoclonal Antibodies Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biologics Monoclonal Antibodies Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Trastuzumab Major Player Table 3. Rituximab Major Player Table 4. Infliximab Major Player Table 5. Adalimumab Major Player Table 6. Other Major Player Table 7. Global Biologics Monoclonal Antibodies Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Cancer Major Player Table 9. Autoimmune Disease Major Player Table 10. Other Major Player Table 11. Biologics Monoclonal Antibodies Drug Industry Trends Table 12. Biologics Monoclonal Antibodies Drug Industry Drivers Table 13. Biologics Monoclonal Antibodies Drug Industry Opportunities and Challenges Table 14. Biologics Monoclonal Antibodies Drug Industry Restraints Table 15. Global Biologics Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Biologics Monoclonal Antibodies Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Biologics Monoclonal Antibodies Drug Market Share by Region (2021-2026) Table 18. Global Biologics Monoclonal Antibodies Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Biologics Monoclonal Antibodies Drug Market Share by Region (2027-2032) Table 20. Global Biologics Monoclonal Antibodies Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Players (2021-2026) Table 22. Global Biologics Monoclonal Antibodies Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Biologics Monoclonal Antibodies Drug Key Players Headquarters & Area Served Table 24. Global Biologics Monoclonal Antibodies Drug Players, Product Type & Application Table 25. Global Biologics Monoclonal Antibodies Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Biologics Monoclonal Antibodies Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Biologics Monoclonal Antibodies Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2021-2026) Table 32. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2027-2032) Table 33. Global Biologics Monoclonal Antibodies Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2021-2026) Table 37. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2027-2032) Table 38. Sanofi Company Information Table 39. Sanofi Business Overview Table 40. Sanofi Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Sanofi Biologics Monoclonal Antibodies Drug Product Portfolio Table 42. Sanofi Recent Development Table 43. Johnson & Johnson Company Information Table 44. Johnson & Johnson Business Overview Table 45. Johnson & Johnson Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Johnson & Johnson Biologics Monoclonal Antibodies Drug Product Portfolio Table 47. Johnson & Johnson Recent Development Table 48. Novartis Company Information Table 49. Novartis Business Overview Table 50. Novartis Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Novartis Biologics Monoclonal Antibodies Drug Product Portfolio Table 52. Novartis Recent Development Table 53. Merck Company Information Table 54. Merck Business Overview Table 55. Merck Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Merck Biologics Monoclonal Antibodies Drug Product Portfolio Table 57. Merck Recent Development Table 58. Roche Company Information Table 59. Roche Business Overview Table 60. Roche Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Roche Biologics Monoclonal Antibodies Drug Product Portfolio Table 62. Roche Recent Development Table 63. Eli Lilly Company Information Table 64. Eli Lilly Business Overview Table 65. Eli Lilly Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Eli Lilly Biologics Monoclonal Antibodies Drug Product Portfolio Table 67. Eli Lilly Recent Development Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Pfizer Biologics Monoclonal Antibodies Drug Product Portfolio Table 72. Pfizer Recent Development Table 73. Biogen Company Information Table 74. Biogen Business Overview Table 75. Biogen Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Biogen Biologics Monoclonal Antibodies Drug Product Portfolio Table 77. Biogen Recent Development Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Amgen Biologics Monoclonal Antibodies Drug Product Portfolio Table 82. Amgen Recent Development Table 83. AbbVie Company Information Table 84. AbbVie Business Overview Table 85. AbbVie Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. AbbVie Biologics Monoclonal Antibodies Drug Product Portfolio Table 87. AbbVie Recent Development Table 88. Sobi Company Information Table 89. Sobi Business Overview Table 90. Sobi Biologics Monoclonal Antibodies Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Sobi Biologics Monoclonal Antibodies Drug Product Portfolio Table 92. Sobi Recent Development Table 93. Innovent Biologics Company Information Table 94. Innovent Biologics Business Overview Table 95. Innovent Biologics Biologics Monoclonal Antibodies Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Innovent Biologics Biologics Monoclonal Antibodies Drug Product Portfolio Table 97. Innovent Biologics Recent Development Table 98. North America Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 99. North America Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 100. North America Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 101. North America Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 102. North America Biologics Monoclonal Antibodies Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. North America Biologics Monoclonal Antibodies Drug Revenue by Country (2021-2026) & (US$ Million) Table 104. North America Biologics Monoclonal Antibodies Drug Revenue by Country (US$ Million) & (2027-2032) Table 105. Europe Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 106. Europe Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 107. Europe Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 108. Europe Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 109. Europe Biologics Monoclonal Antibodies Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Europe Biologics Monoclonal Antibodies Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Biologics Monoclonal Antibodies Drug Revenue by Country (US$ Million) & (2027-2032) Table 112. China Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 113. China Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 114. China Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 115. China Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 116. Asia Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 117. Asia Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 118. Asia Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 119. Asia Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia Biologics Monoclonal Antibodies Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Asia Biologics Monoclonal Antibodies Drug Revenue by Region (US$ Million) & (2021-2026) Table 122. Asia Biologics Monoclonal Antibodies Drug Revenue by Region (US$ Million) & (2027-2032) Table 123. SAMEA Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 124. SAMEA Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 125. SAMEA Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 126. SAMEA Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 127. SAMEA Biologics Monoclonal Antibodies Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. SAMEA Biologics Monoclonal Antibodies Drug Revenue by Country (2021-2026) & (US$ Million) Table 129. SAMEA Biologics Monoclonal Antibodies Drug Revenue by Country (US$ Million) & (2027-2032) Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Biologics Monoclonal Antibodies Drug Image Figure 2. Global Biologics Monoclonal Antibodies Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics Monoclonal Antibodies Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Trastuzumab Image Figure 5. Rituximab Image Figure 6. Infliximab Image Figure 7. Adalimumab Image Figure 8. Other Image Figure 9. Global Biologics Monoclonal Antibodies Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Biologics Monoclonal Antibodies Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Cancer Image Figure 12. Autoimmune Disease Image Figure 13. Other Image Figure 14. Global Biologics Monoclonal Antibodies Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global Biologics Monoclonal Antibodies Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Biologics Monoclonal Antibodies Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Biologics Monoclonal Antibodies Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Biologics Monoclonal Antibodies Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Biologics Monoclonal Antibodies Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Biologics Monoclonal Antibodies Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Biologics Monoclonal Antibodies Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Biologics Monoclonal Antibodies Drug Revenue Share by Type (2021-2032) Figure 27. North America Biologics Monoclonal Antibodies Drug Revenue Share by Application (2021-2032) Figure 28. North America Biologics Monoclonal Antibodies Drug Revenue Share by Country (2021-2032) Figure 29. United States Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Biologics Monoclonal Antibodies Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Biologics Monoclonal Antibodies Drug Revenue Share by Type (2021-2032) Figure 34. Europe Biologics Monoclonal Antibodies Drug Revenue Share by Application (2021-2032) Figure 35. Europe Biologics Monoclonal Antibodies Drug Revenue Share by Country (2021-2032) Figure 36. Germany Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Biologics Monoclonal Antibodies Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Biologics Monoclonal Antibodies Drug Revenue Share by Type (2021-2032) Figure 46. China Biologics Monoclonal Antibodies Drug Revenue Share by Application (2021-2032) Figure 47. Asia Biologics Monoclonal Antibodies Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Biologics Monoclonal Antibodies Drug Revenue Share by Type (2021-2032) Figure 49. Asia Biologics Monoclonal Antibodies Drug Revenue Share by Application (2021-2032) Figure 50. Asia Biologics Monoclonal Antibodies Drug Revenue Share by Region (2021-2032) Figure 51. Japan Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Biologics Monoclonal Antibodies Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Biologics Monoclonal Antibodies Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Biologics Monoclonal Antibodies Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA Biologics Monoclonal Antibodies Drug Revenue Share by Country (2021-2032) Figure 61. Brazil Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Biologics Monoclonal Antibodies Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Trastuzumab
  • Rituximab
  • Infliximab
  • Adalimumab
  • Other
Applications
  • Cancer
  • Autoimmune Disease
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Biogen
  • Amgen
  • AbbVie
  • Sobi
  • Innovent Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biologics Monoclonal Antibodies Drug Market by Type
  3. 1.2.1 Global Biologics Monoclonal Antibodies Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Trastuzumab
  5. 1.2.3 Rituximab
  6. 1.2.4 Infliximab
  7. 1.2.5 Adalimumab
  8. 1.2.6 Other
  9. 1.3 Biologics Monoclonal Antibodies Drug Market by Application
  10. 1.3.1 Global Biologics Monoclonal Antibodies Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Cancer
  12. 1.3.3 Autoimmune Disease
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Biologics Monoclonal Antibodies Drug Market Dynamics
  1. 2.1 Biologics Monoclonal Antibodies Drug Industry Trends
  2. 2.2 Biologics Monoclonal Antibodies Drug Industry Drivers
  3. 2.3 Biologics Monoclonal Antibodies Drug Industry Opportunities and Challenges
  4. 2.4 Biologics Monoclonal Antibodies Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Biologics Monoclonal Antibodies Drug Market Perspective (2021-2032)
  2. 3.2 Global Biologics Monoclonal Antibodies Drug Growth Trends by Region
  3. 3.2.1 Global Biologics Monoclonal Antibodies Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biologics Monoclonal Antibodies Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Biologics Monoclonal Antibodies Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Biologics Monoclonal Antibodies Drug Revenue by Players
  2. 4.1.1 Global Biologics Monoclonal Antibodies Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Biologics Monoclonal Antibodies Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biologics Monoclonal Antibodies Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Biologics Monoclonal Antibodies Drug Key Players Headquarters & Area Served
  7. 4.4 Global Biologics Monoclonal Antibodies Drug Players, Product Type & Application
  8. 4.5 Global Biologics Monoclonal Antibodies Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Biologics Monoclonal Antibodies Drug Market CR5 and HHI
  11. 4.6.3 2025 Biologics Monoclonal Antibodies Drug Tier 1, Tier 2, and Tier 3
5 Biologics Monoclonal Antibodies Drug Market Size by Type
  1. 5.1 Global Biologics Monoclonal Antibodies Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 5.3 Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2021-2032)
6 Biologics Monoclonal Antibodies Drug Market Size by Application
  1. 6.1 Global Biologics Monoclonal Antibodies Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  3. 6.3 Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Biologics Monoclonal Antibodies Drug Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Biologics Monoclonal Antibodies Drug Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Biologics Monoclonal Antibodies Drug Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck Biologics Monoclonal Antibodies Drug Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Biologics Monoclonal Antibodies Drug Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Eli Lilly
  32. 7.6.1 Eli Lilly Company Information
  33. 7.6.2 Eli Lilly Business Overview
  34. 7.6.3 Eli Lilly Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly Biologics Monoclonal Antibodies Drug Product Portfolio
  36. 7.6.5 Eli Lilly Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Biologics Monoclonal Antibodies Drug Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Biogen
  44. 7.8.1 Biogen Company Information
  45. 7.8.2 Biogen Business Overview
  46. 7.8.3 Biogen Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biogen Biologics Monoclonal Antibodies Drug Product Portfolio
  48. 7.8.5 Biogen Recent Developments
  49. 7.9 Amgen
  50. 7.9.1 Amgen Company Information
  51. 7.9.2 Amgen Business Overview
  52. 7.9.3 Amgen Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Amgen Biologics Monoclonal Antibodies Drug Product Portfolio
  54. 7.9.5 Amgen Recent Developments
  55. 7.10 AbbVie
  56. 7.10.1 AbbVie Company Information
  57. 7.10.2 AbbVie Business Overview
  58. 7.10.3 AbbVie Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AbbVie Biologics Monoclonal Antibodies Drug Product Portfolio
  60. 7.10.5 AbbVie Recent Developments
  61. 7.11 Sobi
  62. 7.11.1 Sobi Company Information
  63. 7.11.2 Sobi Business Overview
  64. 7.11.3 Sobi Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sobi Biologics Monoclonal Antibodies Drug Product Portfolio
  66. 7.11.5 Sobi Recent Developments
  67. 7.12 Innovent Biologics
  68. 7.12.1 Innovent Biologics Company Information
  69. 7.12.2 Innovent Biologics Business Overview
  70. 7.12.3 Innovent Biologics Biologics Monoclonal Antibodies Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Innovent Biologics Biologics Monoclonal Antibodies Drug Product Portfolio
  72. 7.12.5 Innovent Biologics Recent Developments
8 North America
  1. 8.1 North America Biologics Monoclonal Antibodies Drug Revenue (2021-2032)
  2. 8.2 North America Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032)
  5. 8.3 North America Biologics Monoclonal Antibodies Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032)
  9. 8.5 North America Biologics Monoclonal Antibodies Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Biologics Monoclonal Antibodies Drug Revenue by Country
  11. 8.6.1 North America Biologics Monoclonal Antibodies Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Biologics Monoclonal Antibodies Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Biologics Monoclonal Antibodies Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Biologics Monoclonal Antibodies Drug Revenue (2021-2032)
  2. 9.2 Europe Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Biologics Monoclonal Antibodies Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Biologics Monoclonal Antibodies Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Biologics Monoclonal Antibodies Drug Revenue by Country
  11. 9.6.1 Europe Biologics Monoclonal Antibodies Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Biologics Monoclonal Antibodies Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Biologics Monoclonal Antibodies Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Biologics Monoclonal Antibodies Drug Revenue (2021-2032)
  2. 10.2 China Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032)
  5. 10.3 China Biologics Monoclonal Antibodies Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032)
  9. 10.5 China Biologics Monoclonal Antibodies Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biologics Monoclonal Antibodies Drug Revenue (2021-2032)
  2. 11.2 Asia Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Biologics Monoclonal Antibodies Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Biologics Monoclonal Antibodies Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Biologics Monoclonal Antibodies Drug Revenue by Country
  11. 11.6.1 Asia Biologics Monoclonal Antibodies Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Biologics Monoclonal Antibodies Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Biologics Monoclonal Antibodies Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biologics Monoclonal Antibodies Drug Revenue (2021-2032)
  2. 12.2 SAMEA Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Biologics Monoclonal Antibodies Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Biologics Monoclonal Antibodies Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Biologics Monoclonal Antibodies Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Biologics Monoclonal Antibodies Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Biologics Monoclonal Antibodies Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Biologics Monoclonal Antibodies Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Biologics Monoclonal Antibodies Drug Revenue by Country
  11. 12.6.1 SAMEA Biologics Monoclonal Antibodies Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Biologics Monoclonal Antibodies Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Biologics Monoclonal Antibodies Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst